Raphael Pharmaceutical Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-223.0K | $-229.0K | $-273.0K | $-255.0K | $-322.0K | $-429.0K | $-395.0K | $-326.0K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | $1.0K | $39.0K | $8.0K | $197.0K | — | — |
| Net Cash from Operating Activities | $0 | $-44.0K | $46.0K | $-17.0K | $-30.0K | $-209.0K | $-62.0K | $-80.0K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | $-4.0K | $0 | $0 | $240.0K | $41.0K | $0 |
| Net Change in Cash | — | — | — | — | — | — | — | $-80.0K |
| Free Cash Flow | — | — | — | — | — | — | — | — |